STAT Plus: Promising results for previously secret cancer drug data that ‘justified’ Gilead Sciences’ $21 billion acquisition

When Gilead Sciences announced its $21 billion acquisition of Immunomedics one week ago, Gilead executives said that clinical data on Immunomedics’ cancer drug Trodelvy — shared confidentially during negotiations — justified the high cost of the deal.

On Saturday, data from Trodelvy studies in bladder cancer and triple-negative breast cancer were presented publicly for the first time at the annual meeting of the European Society for Medical Oncology.

Continue to STAT Plus to read the full story…

Read Original Article: STAT Plus: Promising results for previously secret cancer drug data that ‘justified’ Gilead Sciences’ $21 billion acquisition »